Cipla USA Faces Nationwide Class III Recall for Diclofenac Sodium Topical Gel Due to Failed pH Specifications
Cipla USA, Inc. has initiated a nationwide Class III recall for 92,376 tubes of Diclofenac Sodium Topical Gel, 1%, manufactured by DPT Laboratories, Ltd., due to failed pH specifications. This voluntary recall, D-0291-2026, highlights critical quality control deficiencies at the manufacturing level, impacting supply chain integrity and demanding immediate action from procurement and regulatory teams.
FDA Initiates Class III Recall for Cipla USA's Diclofenac Sodium Topical Gel
Cipla USA, Inc., based in Warren, NJ, has voluntarily initiated a nationwide Class III recall, designated D-0291-2026, for its Diclofenac Sodium Topical Gel, 1%. This significant action, initiated on December 22, 2025, impacts 92,376 tubes of the product, distributed across the United States. The affected product, identified by NDC 76282-103-39 and manufactured by DPT Laboratories, Ltd. in San Antonio, TX, is a human OTC drug primarily used for topical application. For procurement directors, this recall necessitates an immediate review of inventory and distribution channels for Diclofenac Sodium Topical Gel, 1%. While a Class III classification indicates that the probability of adverse health consequences is remote, the logistical and financial implications of retrieving nearly 100,000 units are substantial. Supply chain VPs must account for potential returns, destruction costs, and the administrative burden associated with managing a nationwide recall. This event underscores the critical need for robust traceability systems to efficiently identify and isolate affected batches, minimizing broader market disruption and financial exposure for your organization.
Manufacturing Quality Failure at DPT Laboratories: Failed pH Specifications
The core reason for Cipla USA's recall of Diclofenac Sodium Topical Gel, 1%, is the product's failure to meet established pH specifications. This critical quality deviation was identified in batch XHBG, with an expiration date of August 31, 2027. DPT Laboratories, Ltd., located at 307 E Josephine Street, San Antonio, TX 78215, is explicitly named as the manufacturer of this specific product batch. For regulatory affairs heads, a failure in pH specifications is a fundamental breach of product quality and Good Manufacturing Practices (cGMP). In topical formulations like Diclofenac Sodium Gel, pH is crucial for drug stability, efficacy, and patient comfort, directly influencing absorption and minimizing skin irritation. This incident points to potential deficiencies in DPT Laboratories' quality control systems, specifically concerning in-process controls or final product release testing. Procurement teams must scrutinize their existing quality agreements with contract manufacturing organizations (CMOs) like DPT Laboratories, ensuring that critical quality attributes, such as pH, are rigorously monitored and verified through comprehensive Certificates of Analysis (CoAs) and robust audit programs. This event demands a re-evaluation of supplier qualification processes to prevent future compliance risks.
Supply Chain and Commercial Impact for Cipla USA's Diclofenac Sodium
The nationwide recall of 92,376 tubes of Diclofenac Sodium Topical Gel, 1%, presents immediate and long-term commercial ramifications for Cipla USA, Inc. and its distribution partners. Business development executives must assess the potential for short-term market disruption and the erosion of brand trust, even with a Class III classification. The logistical complexity of retrieving a product distributed across the entire USA will incur significant costs, including reverse logistics, warehousing, and disposal, directly impacting profitability for the affected batch. Furthermore, the event may prompt pharmacies and wholesalers to re-evaluate their reliance on Cipla USA for this specific product, potentially leading to lost sales and market share. Supply chain VPs need to activate contingency plans to ensure continuity of supply for Diclofenac Sodium from unaffected batches or alternative sources, if available, to mitigate customer dissatisfaction. This recall serves as a stark reminder that manufacturing quality issues at a contract partner, such as DPT Laboratories, Ltd., directly translate into commercial liabilities and reputational damage for the marketing authorization holder, Cipla USA.
Proactive Risk Mitigation: Strategic Sourcing for Topical Pharmaceutical Formulations
In light of the Cipla USA recall stemming from DPT Laboratories' manufacturing issues, procurement directors must prioritize strategic sourcing and robust quality assurance for all topical pharmaceutical formulations, including Diclofenac Sodium. While specific alternative suppliers are not identified in the available intelligence, this incident underscores the imperative for diversifying manufacturing partners to mitigate single-source dependencies. Implementing a rigorous supplier qualification program, extending beyond initial audits to include ongoing performance monitoring and periodic re-audits, is crucial. Regulatory affairs heads must ensure that quality agreements with all contract manufacturers explicitly define critical quality parameters like pH, specify testing methodologies, and outline clear responsibilities for deviation management. Proactive risk management, including scenario planning for supply disruptions and maintaining a portfolio of qualified manufacturers for essential molecules, will safeguard against similar compliance failures. This approach minimizes commercial exposure and ensures uninterrupted patient access to critical medications, reinforcing the resilience of your global chemical and life sciences supply chain.